search
Back to results

The Impact Of An Intermittent Energy Restricted Diet On Insulin Sensitivity In Men and Women With Central Obesity (Met-IER)

Primary Purpose

Obesity, Abdominal

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Intermittent Energy Restriction
Continuous Energy Restriction
Sponsored by
King's College London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Obesity, Abdominal focused on measuring Insulin sensitivity, Weight loss, Intermittent fasting, Sympathetic nervous system

Eligibility Criteria

35 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Aged >35-75 years
  • Waist circumference above cut-off for high risk of cardio-metabolic disease of >102 cm in men with a Europid, Black African and Caribbean, and other ethnic background and >88 cm in women with a Europid, Black African and Caribbean, and other ethnic background (WHO, 2008), and ≥90 cm in men and ≥80 cm in women with an Asian background (South Asian and East Asian) (Misra et al., 2009).

REFERENCES Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. (2009). Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. The Journal of the Association of Physicians of India 57: 163170.

WHO (2008). Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva, 8-11 December 2008.

Exclusion Criteria:

  • Kidney or cardiovascular disease, cancer, diabetes, gastrointestinal or chronic liver disease;
  • previous bariatric surgery or other major surgery (e.g. organ transplantation);
  • unable to provide written informed consent;
  • have significant psychiatric disorder (e.g. schizophrenia, anxiety, panic disorder, attention deficit disorder, post-traumatic stress disorder, obsessive compulsive disorder) or uncontrolled depression;
  • participated in a weight management drug trial in the previous 3 months;
  • have binge eating behaviour;
  • have uncontrolled epilepsy;
  • alcohol or substance abuse;
  • currently pregnant, lactating, or planning pregnancy within the study period;
  • are using medication clinically deemed to affect metabolic rate and weight (e.g. beta blockers, corticosteroids, diuretics, etc);
  • lactose intolerant.

Sites / Locations

  • Diabetes & Nutritional Sciences Division, King's College London, Franklin-Wilkins Buiding, 150 Stamford St.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intermittent Energy Restriction

Continuous Energy Restriction

Arm Description

Weight loss intervention: Intermittent Energy Restriction

Weight loss intervention: Continuous Energy Restriction

Outcomes

Primary Outcome Measures

Revised QUICKI (RQUICKI)
Marker of insulin sensitivity
RQUICKI
Marker of insulin sensitivity
RQUICKI
Marker of insulin sensitivity

Secondary Outcome Measures

Plasma glucose concentration
Fasting
Plasma glucose concentration
Fasting
Plasma glucose concentration
Fasting
Plasma insulin concentration
Fasting
Plasma insulin concentration
Fasting
Plasma insulin concentration
Fasting
Plasma non-esterified fatty acid concentration
Fasting
Plasma non-esterified fatty acid concentration
Fasting
Plasma non-esterified fatty acid concentration
Fasting
Plasma total cholesterol concentration
Fasting
Plasma total cholesterol concentration
Fasting
Plasma total cholesterol concentration
Fasting
Plasma low density lipoprotein (LDL) cholesterol concentration
Fasting
Plasma LDL cholesterol concentration
Fasting
Plasma LDL cholesterol concentration
Fasting
Plasma high density lipoprotein (HDL) cholesterol concentration
Fasting
Plasma HDL cholesterol concentration
Fasting
Plasma HDL cholesterol concentration
Fasting
Plasma triglyceride concentration
Fasting
Plasma triglyceride concentration
Fasting
Plasma triglyceride concentration
Fasting
Plasma total cholesterol:HDL cholesterol ratio
Fasting
Plasma total cholesterol:HDL cholesterol ratio
Fasting
Plasma total cholesterol:HDL cholesterol ratio
Fasting
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Fasting (calculated from insulin and glucose)
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Fasting (calculated from insulin and glucose)
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Fasting (calculated from insulin and glucose)
Plasma adiponectin concentration
Fasting
Plasma adiponectin concentration
Fasting
Plasma adiponectin concentration
Fasting
Plasma leptin concentration
Fasting
Plasma leptin concentration
Fasting
Plasma leptin concentration
Fasting
Plasma interleukin-6 concentration
Fasting
Plasma interleukin-6 concentration
Fasting
Plasma interleukin-6 concentration
Fasting
Plasma beta-hydroxybutyrate concentration
Fasting
Plasma beta-hydroxybutyrate concentration
Fasting
Plasma beta-hydroxybutyrate concentration
Fasting
Plasma norepinephrine concentration
Fasting
Plasma norepinephrine concentration
Fasting
Plasma norepinephrine concentration
Fasting
Plasma soluble alpha-klotho concentration
Fasting
Plasma soluble alpha-klotho concentration
Fasting
Plasma soluble alpha-klotho concentration
Fasting
Body weight
Body weight
Body weight
Body mass index (BMI)
BMI
BMI
Waist circumference
Waist circumference
Waist circumference
Hip circumference
Hip circumference
Hip circumference
Percentage body fat
Percentage body fat
Percentage body fat
Percentage lean body mass
Percentage lean body mass
Percentage lean body mass
Heart rate variability (resting)
supine
Heart rate variability (resting)
supine
Heart rate variability (resting)
supine
Heart rate variability (ambulatory)
Heart rate variability (ambulatory)
Heart rate variability (ambulatory)
Heart rate variability (sleep-time)
Heart rate variability (sleep-time)
Heart rate variability (sleep-time)
Heart rate variability (during mental stress)
Heart rate variability (during mental stress)
Heart rate variability (during mental stress)
Ambulatory blood pressure 24 h
Ambulatory blood pressure daytime
Ambulatory blood pressure night-time
Ambulatory blood pressure 24 h
Ambulatory blood pressure daytime
Ambulatory blood pressure night-time
Ambulatory blood pressure 24 h
24 h
Ambulatory blood pressure daytime
day time
Ambulatory blood pressure night-time
night-time
Digital volume pulse - stiffness index (SI)
Stiffness index
Digital volume pulse - SI
Stiffness index
Digital volume pulse - SI
Stiffness index
Digital volume pulse - reflection index (RI)
reflection index
Digital volume pulse - RI
reflection index
Digital volume pulse - RI
reflection index
Mnemonic Similarity Test
Mnemonic Similarity Test
Mnemonic Similarity Test
Power of food scale
questionnaire
Power of food scale
questionnaire
Power of food scale
questionnaire
COPE (not an acronym)
questionnaire
COPE
questionnaire
COPE
questionnaire

Full Information

First Posted
January 22, 2016
Last Updated
September 13, 2019
Sponsor
King's College London
Collaborators
LighterLife (UK) Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT02679989
Brief Title
The Impact Of An Intermittent Energy Restricted Diet On Insulin Sensitivity In Men and Women With Central Obesity
Acronym
Met-IER
Official Title
A Randomised Controlled Trial Assessing The Impact Of An Intermittent Energy Restricted Diet On Weight Loss, Insulin Sensitivity and Heart Rate Variability In Men and Women With Central Obesity
Study Type
Interventional

2. Study Status

Record Verification Date
July 2016
Overall Recruitment Status
Completed
Study Start Date
February 2016 (undefined)
Primary Completion Date
July 2016 (Actual)
Study Completion Date
July 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
King's College London
Collaborators
LighterLife (UK) Ltd

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
An intermittent energy restricted (IER) diet may modify cardio-metabolic disease risk factors compared to an energy-matched continuous energy restricted (CER) diet. A randomised controlled parallel design trial will determine the impact of a short-term IER diet (2 consecutive days of very low calorie diet (VLCD), 5 days moderate energy restriction each week for a 4 week period), compared to a CER diet, on insulin sensitivity in healthy (disease-free) subjects with central obesity.
Detailed Description
Prediabetes rates in England have showed a marked increase, more than tripling between 2003 and 2011. It is characterised by an impaired fasting glucose or impaired glucose tolerance that increases the risk of progression to type 2 diabetes (T2D). It has been estimated that approximately 90% of T2D is attributed to excess weight. Central obesity is a primary driver of increased cardiometabolic risk due to its lipotoxicity effects, promoting a proinflammatory state that facilitates insulin resistance and beta cell dysfunction. A high waist circumference measurement, indicative of central obesity, is associated with increased risk of cardiovascular diseases and T2D, and is a stronger predictor of T2D than BMI. BMI has limitations as an indicator of adiposity since it doesn't distinguish lean from fat mass, and does not indicate body fat distribution. Conventionally, continuous energy restriction (CER) diets have been used for weight loss, which consist of a constant daily energy deficit relative to total energy expenditure. The impact on weight loss and health of an intermittent energy restriction (IER) approach has only rarely been investigated (although the "5:2 diet" has been popularised in lifestyle books aimed at the general public). An IER diet consists of a predefined period of time severely restricting energy intake, alternated with a period of greater energy intake. This approach was shown to confer metabolic benefits in overweight and obese women at risk of breast cancer with baseline BMI of 2445 (Harvie et al., 2013; Harvie et al., 2011). Rationale: An IER diet using meal replacements (VLCD foodpacks used as total dietary replacements for 2 consecutive days each week, and a food-based energy-restricted diet for the other 5 days of the week) may modify cardio-metabolic disease risk factors compared to an energy-matched CER diet. Research question: In centrally obese subjects, assessed by a high waist circumference measurement, does adherence to an IER diet have enhanced cardio-metabolic benefits compared to a CER diet? Hypothesis: Increases in insulin sensitivity following a 4 week dietary intervention with an IER weight loss programme will be greater compared to a standard CER programme. Objectives: A randomised controlled parallel design trial will determine the impact of a short-term IER diet compared to a CER diet on primary outcome variables (insulin sensitivity) in healthy subjects with a high waist circumference. To assess the impact of an IER diet on secondary outcome variables, including body composition, heart rate variability (HRV, a measure of cardiac autonomic function, including parasympathetic and sympathetic activity), blood pressure, vascular function, other markers of insulin resistance, inflammation/adipokines, plasma lipid profile, plasma norepinephrine, ketosis, the gut microbiome and cognitive function in healthy subjects with a high waist circumference.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Abdominal
Keywords
Insulin sensitivity, Weight loss, Intermittent fasting, Sympathetic nervous system

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
42 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intermittent Energy Restriction
Arm Type
Experimental
Arm Description
Weight loss intervention: Intermittent Energy Restriction
Arm Title
Continuous Energy Restriction
Arm Type
Active Comparator
Arm Description
Weight loss intervention: Continuous Energy Restriction
Intervention Type
Behavioral
Intervention Name(s)
Intermittent Energy Restriction
Intervention Description
Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
Intervention Type
Behavioral
Intervention Name(s)
Continuous Energy Restriction
Intervention Description
Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions
Primary Outcome Measure Information:
Title
Revised QUICKI (RQUICKI)
Description
Marker of insulin sensitivity
Time Frame
Baseline
Title
RQUICKI
Description
Marker of insulin sensitivity
Time Frame
day 29
Title
RQUICKI
Description
Marker of insulin sensitivity
Time Frame
day 31
Secondary Outcome Measure Information:
Title
Plasma glucose concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma glucose concentration
Description
Fasting
Time Frame
day 29
Title
Plasma glucose concentration
Description
Fasting
Time Frame
day 31
Title
Plasma insulin concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma insulin concentration
Description
Fasting
Time Frame
day 29
Title
Plasma insulin concentration
Description
Fasting
Time Frame
day 31
Title
Plasma non-esterified fatty acid concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma non-esterified fatty acid concentration
Description
Fasting
Time Frame
day 29
Title
Plasma non-esterified fatty acid concentration
Description
Fasting
Time Frame
day 31
Title
Plasma total cholesterol concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma total cholesterol concentration
Description
Fasting
Time Frame
day 29
Title
Plasma total cholesterol concentration
Description
Fasting
Time Frame
day 31
Title
Plasma low density lipoprotein (LDL) cholesterol concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma LDL cholesterol concentration
Description
Fasting
Time Frame
day 29
Title
Plasma LDL cholesterol concentration
Description
Fasting
Time Frame
day 31
Title
Plasma high density lipoprotein (HDL) cholesterol concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma HDL cholesterol concentration
Description
Fasting
Time Frame
day 29
Title
Plasma HDL cholesterol concentration
Description
Fasting
Time Frame
day 31
Title
Plasma triglyceride concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma triglyceride concentration
Description
Fasting
Time Frame
day 29
Title
Plasma triglyceride concentration
Description
Fasting
Time Frame
day 31
Title
Plasma total cholesterol:HDL cholesterol ratio
Description
Fasting
Time Frame
Baseline
Title
Plasma total cholesterol:HDL cholesterol ratio
Description
Fasting
Time Frame
day 29
Title
Plasma total cholesterol:HDL cholesterol ratio
Description
Fasting
Time Frame
day 31
Title
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Description
Fasting (calculated from insulin and glucose)
Time Frame
Baseline
Title
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Description
Fasting (calculated from insulin and glucose)
Time Frame
day 29
Title
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Description
Fasting (calculated from insulin and glucose)
Time Frame
day 31
Title
Plasma adiponectin concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma adiponectin concentration
Description
Fasting
Time Frame
day 29
Title
Plasma adiponectin concentration
Description
Fasting
Time Frame
day 31
Title
Plasma leptin concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma leptin concentration
Description
Fasting
Time Frame
day 29
Title
Plasma leptin concentration
Description
Fasting
Time Frame
day 31
Title
Plasma interleukin-6 concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma interleukin-6 concentration
Description
Fasting
Time Frame
day 29
Title
Plasma interleukin-6 concentration
Description
Fasting
Time Frame
day 31
Title
Plasma beta-hydroxybutyrate concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma beta-hydroxybutyrate concentration
Description
Fasting
Time Frame
day 29
Title
Plasma beta-hydroxybutyrate concentration
Description
Fasting
Time Frame
day 31
Title
Plasma norepinephrine concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma norepinephrine concentration
Description
Fasting
Time Frame
day 29
Title
Plasma norepinephrine concentration
Description
Fasting
Time Frame
day 31
Title
Plasma soluble alpha-klotho concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma soluble alpha-klotho concentration
Description
Fasting
Time Frame
day 29
Title
Plasma soluble alpha-klotho concentration
Description
Fasting
Time Frame
day 31
Title
Body weight
Time Frame
Baseline
Title
Body weight
Time Frame
day 29
Title
Body weight
Time Frame
day 31
Title
Body mass index (BMI)
Time Frame
Baseline
Title
BMI
Time Frame
day 29
Title
BMI
Time Frame
day 31
Title
Waist circumference
Time Frame
Baseline
Title
Waist circumference
Time Frame
day 29
Title
Waist circumference
Time Frame
day 31
Title
Hip circumference
Time Frame
Baseline
Title
Hip circumference
Time Frame
day 29
Title
Hip circumference
Time Frame
day 31
Title
Percentage body fat
Time Frame
Baseline
Title
Percentage body fat
Time Frame
day 29
Title
Percentage body fat
Time Frame
day 31
Title
Percentage lean body mass
Time Frame
Baseline
Title
Percentage lean body mass
Time Frame
day 29
Title
Percentage lean body mass
Time Frame
day 31
Title
Heart rate variability (resting)
Description
supine
Time Frame
Baseline
Title
Heart rate variability (resting)
Description
supine
Time Frame
day 29
Title
Heart rate variability (resting)
Description
supine
Time Frame
day 31
Title
Heart rate variability (ambulatory)
Time Frame
24 h recording at baseline
Title
Heart rate variability (ambulatory)
Time Frame
24 h recording on day 29
Title
Heart rate variability (ambulatory)
Time Frame
24 h recording on day 31
Title
Heart rate variability (sleep-time)
Time Frame
Baseline
Title
Heart rate variability (sleep-time)
Time Frame
day 29
Title
Heart rate variability (sleep-time)
Time Frame
day 31
Title
Heart rate variability (during mental stress)
Time Frame
Baseline
Title
Heart rate variability (during mental stress)
Time Frame
day 29
Title
Heart rate variability (during mental stress)
Time Frame
day 31
Title
Ambulatory blood pressure 24 h
Time Frame
24 h analysis at baseline
Title
Ambulatory blood pressure daytime
Time Frame
Daytime analysis at baseline
Title
Ambulatory blood pressure night-time
Time Frame
Night-time analysis at baseline
Title
Ambulatory blood pressure 24 h
Time Frame
24 h analysis on day 29
Title
Ambulatory blood pressure daytime
Time Frame
daytime analysis on day 29
Title
Ambulatory blood pressure night-time
Time Frame
night-time analysis on day 29
Title
Ambulatory blood pressure 24 h
Description
24 h
Time Frame
24 h analysis on day 31
Title
Ambulatory blood pressure daytime
Description
day time
Time Frame
Daytime analysis on day 31
Title
Ambulatory blood pressure night-time
Description
night-time
Time Frame
Night-time analysis on day 31
Title
Digital volume pulse - stiffness index (SI)
Description
Stiffness index
Time Frame
Baseline
Title
Digital volume pulse - SI
Description
Stiffness index
Time Frame
day 29
Title
Digital volume pulse - SI
Description
Stiffness index
Time Frame
day 31
Title
Digital volume pulse - reflection index (RI)
Description
reflection index
Time Frame
Baseline
Title
Digital volume pulse - RI
Description
reflection index
Time Frame
day 29
Title
Digital volume pulse - RI
Description
reflection index
Time Frame
day 31
Title
Mnemonic Similarity Test
Time Frame
Baseline
Title
Mnemonic Similarity Test
Time Frame
day 29
Title
Mnemonic Similarity Test
Time Frame
day 31
Title
Power of food scale
Description
questionnaire
Time Frame
Baseline
Title
Power of food scale
Description
questionnaire
Time Frame
day 29
Title
Power of food scale
Description
questionnaire
Time Frame
day 31
Title
COPE (not an acronym)
Description
questionnaire
Time Frame
Baseline
Title
COPE
Description
questionnaire
Time Frame
day 29
Title
COPE
Description
questionnaire
Time Frame
day 31
Other Pre-specified Outcome Measures:
Title
Adverse events
Time Frame
Baseline until endpoint: day 31 (+/-1 day)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Aged >35-75 years Waist circumference above cut-off for high risk of cardio-metabolic disease of >102 cm in men with a Europid, Black African and Caribbean, and other ethnic background and >88 cm in women with a Europid, Black African and Caribbean, and other ethnic background (WHO, 2008), and ≥90 cm in men and ≥80 cm in women with an Asian background (South Asian and East Asian) (Misra et al., 2009). REFERENCES Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. (2009). Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. The Journal of the Association of Physicians of India 57: 163170. WHO (2008). Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva, 8-11 December 2008. Exclusion Criteria: Kidney or cardiovascular disease, cancer, diabetes, gastrointestinal or chronic liver disease; previous bariatric surgery or other major surgery (e.g. organ transplantation); unable to provide written informed consent; have significant psychiatric disorder (e.g. schizophrenia, anxiety, panic disorder, attention deficit disorder, post-traumatic stress disorder, obsessive compulsive disorder) or uncontrolled depression; participated in a weight management drug trial in the previous 3 months; have binge eating behaviour; have uncontrolled epilepsy; alcohol or substance abuse; currently pregnant, lactating, or planning pregnancy within the study period; are using medication clinically deemed to affect metabolic rate and weight (e.g. beta blockers, corticosteroids, diuretics, etc); lactose intolerant.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wendy Hall, PhD
Organizational Affiliation
King's College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
Diabetes & Nutritional Sciences Division, King's College London, Franklin-Wilkins Buiding, 150 Stamford St.
City
London
State/Province
England
ZIP/Postal Code
SE1 9NH
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
23591120
Citation
Harvie M, Wright C, Pegington M, McMullan D, Mitchell E, Martin B, Cutler RG, Evans G, Whiteside S, Maudsley S, Camandola S, Wang R, Carlson OD, Egan JM, Mattson MP, Howell A. The effect of intermittent energy and carbohydrate restriction v. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. Br J Nutr. 2013 Oct;110(8):1534-47. doi: 10.1017/S0007114513000792. Epub 2013 Apr 16.
Results Reference
background
PubMed Identifier
20921964
Citation
Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, Cuzick J, Jebb SA, Martin B, Cutler RG, Son TG, Maudsley S, Carlson OD, Egan JM, Flyvbjerg A, Howell A. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond). 2011 May;35(5):714-27. doi: 10.1038/ijo.2010.171. Epub 2010 Oct 5.
Results Reference
background
PubMed Identifier
33512717
Citation
Allaf M, Elghazaly H, Mohamed OG, Fareen MFK, Zaman S, Salmasi AM, Tsilidis K, Dehghan A. Intermittent fasting for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2021 Jan 29;1(1):CD013496. doi: 10.1002/14651858.CD013496.pub2.
Results Reference
derived
PubMed Identifier
32121111
Citation
Kim C, Pinto AM, Bordoli C, Buckner LP, Kaplan PC, Del Arenal IM, Jeffcock EJ, Hall WL, Thuret S. Energy Restriction Enhances Adult Hippocampal Neurogenesis-Associated Memory after Four Weeks in an Adult Human Population with Central Obesity; a Randomized Controlled Trial. Nutrients. 2020 Feb 28;12(3):638. doi: 10.3390/nu12030638.
Results Reference
derived
PubMed Identifier
31409509
Citation
Pinto AM, Bordoli C, Buckner LP, Kim C, Kaplan PC, Del Arenal IM, Jeffcock EJ, Hall WL. Intermittent energy restriction is comparable to continuous energy restriction for cardiometabolic health in adults with central obesity: A randomized controlled trial; the Met-IER study. Clin Nutr. 2020 Jun;39(6):1753-1763. doi: 10.1016/j.clnu.2019.07.014. Epub 2019 Jul 30.
Results Reference
derived
Links:
URL
http://www.ncbi.nlm.nih.gov/pubmed/31409509
Description
Primary publication

Learn more about this trial

The Impact Of An Intermittent Energy Restricted Diet On Insulin Sensitivity In Men and Women With Central Obesity

We'll reach out to this number within 24 hrs